-

This activity is provided by Physicians’ Education Resource®, LLC.

An application has been made to the EACCME® for CME accreditation of this event.

• Medical_Professionals
• Medical_students
• Nurses

How do you assimilate the recent advances for the treatment of lymphoid malignancies and apply them to your patients? It is a challenge. What is great news for the field also adds to the complexity of managing these malignancies in real-world practice settings.

Our ability to characterize tumors, stratify risk, and manage lymphoid malignancies continues to evolve at a rapid pace. Sophisticated molecular techniques, which are used to individualize risk stratification and guide treatment, as well as novel targeted and immunotherapeutic options has expanded the treatment armamentarium in the field. The fast pace at which practice-changing evidence continues to emerge poses a constant challenge for clinicians to maintain cutting-edge practice in managing patients with these tumors. Although optimized outcomes depend on the incorporation of novel strategies and proactive mitigation of predictable treatment-related adverse events, it is essential that practitioners have the ability to contextualize landmark trial findings and apply them to their patients.

The 2nd Annual European Congress on Hematology™: Focus on Lymphoid Malignancies is a highly practical and interactive multi-day program that will improve patient care for the clinician who manages patients with lymphoid malignancies. The exciting case-based format is back by popular demand at this year’s Congress, where leading international experts will participate in informative lectures and panels that will discuss recent data sets. What sets this meeting apart are the interactive discussions at the Congress where participants will be challenged to engage directly with renowned faculty to share their perspectives, personal experiences, and methods to address clinical challenges in the management of lymphoid malignancies.

Target Audience

This educational activity is directed toward healthcare professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.) involved in the treatment and management of patients with hematologic malignancies.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

Assess methods to stratify risk using genomic and molecular biomarkers and how they can be used to guide clinical decision-making in the management of hematologic malignancies

Explain key evidence and how it can be applied to real-world clinical scenarios to individualize care

Identify interprofessional approaches to address treatment-related toxicities in patients who receive care for hematologic malignancies

Detail how to ensure compliance among patients who receive oral therapies for the management of their hematological malignancies

Describe emerging mechanistic approaches and evidence concerning novel strategies undergoing clinical development

Place recent clinical trial findings on emerging treatment strategies in the context of evolving treatment paradigms in the field

Stephen Ansell, MD, PhD

Professor of Medicine, Mayo Clinic College of Medicine

Chair, Lymphoma Group, Division of Hematology

Co-Program Leader, Hematologic Malignancies Program, Mayo Clinic Cancer Center

Mayo Clinic

Rochester, MN, USA

Michel Attal, MD, PhD

Professor of Hematology

Paul Sabatier University

Toulouse, France

Christian Gisselbrecht, MD

Professor of Hematology

Paris Diderot University VII

Paris, France

Andre Goy, MD, MS

Executive Director John Theurer Cancer Center

Director of Oncology for Hackensack Meridian Health

Lydia Pfund Chair for Lymphoma

Chair Oncology Seton Hall University

Professor of Medicine, Georgetown University, DC

Hackensack, NJ, USA

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci

Chair of Medical Oncology

Barts Cancer Institute

Barts and The London School of Medicine

Queen Mary University of London

London, England, United Kingdom

Steven Le Gouill, MD, PhD

Clinical Hematology Department

University Hospital of Nantes

Nantes, France

Ronald Levy, MD

Professor

Division of Oncology

Stanford School of Medicine

Stanford, California, USA

Robert Marcus, MA, FRCP, FRCPath

Kings College Hospital

London, UK

María-Victoria Mateos, MD, PhD

Associate Professor, Hematology

University Hospital of Salamanca

Salamanca, Spain

Thomas E. Witzig, MD

Professor of Medicine Mayo Clinic College of Medicine

Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE

Deputy Director of Clinical Research, Mayo Clinic Cancer Center

Rochester, MN, USA

EUR

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

The Westin Paris-Vendôme

3 Rue De Castiglione

Paris, 75001, France

Tel: +33 (0) 1 44 77 11 11

http://www.thewestinparis.fr

The Westin Paris - Vendôme is centrally located in Paris' first arrondissement. The hotel is only a 10-minute walk to Concorde, the Louvre Museum and the Place Vendôme.

Be sure to mention the International Congress on Hematologic Malignancies® when making reservations to receive the discounted rate.  

Room Rates

A limited block of rooms has been set aside at The Westin Paris - Vendôme at a run-of-house rate of €320 single/€340 doube (includes daily breakfast, state and local taxes). Rates and rooms are subject to availability at the time of the reservation.

The deadline for making your hotel reservations is 1 October 2017. After that date, or in the event that the room block becomes full prior to the deadline, rooms are subject to availability, and the room rates may increase. When booking, please mention the 2nd Annual European Congress on Hematology (Paris Lymphoma) to receive the discounted group rate. All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card.

Check-in is 15:00, and check-out is 12:00.

Submission Info

2nd Annual European Congress on Hematology™: Focus on Lymphoid Malignancies -- Call for Poster Abstracts!

The European Congress on Hematology™: Focus on Lymphoid Malignancies Program Chairs invite you to submit your abstracts for the 2nd Annual European Congress on Hematology™: Focus on Lymphoid Malignancies to be held 20 and 21 October 2017, at The Westin Paris-Vendôme in Paris, France.

Deadline for submission is 8 September 2017, at 11:59 AM US EDT (5:59 CEDT).

All poster abstracts must be submitted electronically through the congress' online abstract submission system.

Your abstract should be a short description of your work focused on Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma, containing all the elements necessary to define your goals and results to the reader. Authors will be required to disclose all financial relationships through the online system, helping to ensure quality and unbiased presentations. The formal poster session is not designated for credit.

Share your research or best practices with your peers. Categories of submission include:

Surgical Oncology

Radiation Oncology

Pathology

Medical Oncology

Imaging/ Radiology

Basic Biology

Epidemiology Risk Assessment/ Prevention

Survivorship

Other

Note: Trial in progress and encore abstracts are accepted.

The Program chairs will evaluate the scientific quality of the submitted abstracts on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed.

Notification of acceptance, or regret, will be delivered via e-mail to the presenter(s) of each poster abstract, by mid-September. Please note that an author is required to be present during the poster session.

If accepted for presentation, abstracts and posters will be available for viewing online on the 2017 congress website during and after the conference. The posters will be displayed for the length of the conference. The presentation at the congress should reflect the submitted abstract title, authorship, and content of the presentation at the congress must match the submitted abstract.

All presenters must register to attend the 2nd Annual European Congress on Hematology™: Focus on Lymphoid Malignancies. Please click here to register.

Submission Process

Complete the abstract template provided on the 2017 European Congress on Hematology™: Focus on Lymphoid Malignancies website.

Limit is 2500 characters (abstract body, including spaces and table).

Upload full abstract or poster where prompted.

Components of the Abstract Body-Limit: 2500 Characters (1 table allowed)

Background/Significance -- What was the problem and why was it important? What knowledge are you building on? What was the intent or goal of the study? What did you want to learn?

Materials and Methods -- What was the trial design? What was the sample? What instruments were used? How were data collected and analyzed?

Results -- What were the findings?

Conclusions -- What do the findings mean?

Abstract Questions

Please submit any questions pertaining to abstract submissions to abstracts@gotoper.com using the subject line "European Congress on Hematology™ Abstract QUESTION."

Author Consent and Waiver of Claims

Each abstract author agrees and certifies that he or she:

Waives any and all claims against Physicians' Education Resource®, LLC, sponsor of the European Congress on Hematology™: Focus on Lymphoid Malignancies, and any review arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract submission deadline 2017-09-18

The title of the abstract should be brief, objectively describing the study. Do not use non-standard abbreviations and commercial names (generic names only). Capitalize only the first word and any proper nouns.

No more than 10 authors can be listed with institutional affiliations, cities and countries only. Mailing addresses and academic degrees should not be mentioned in the author's list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations or include the name of the group in the title of the abstract.

First Author (Presenting Author): The name, institution, telephone number, and email address of the First Author is required. The First Author (Presenting Author) will receive all future correspondence from Physicians' Education Resource®.

Abstracts should be structured in such a way as to include the following 4 sections

Background: an introductory sentence indicating the purpose of the study

Material and methods: a brief description of pertinent experimental procedures

Results: a summary of the results of the research

Conclusions: a statement of the main conclusions

Abstracts should not exceed 2,500 characters (body of the abstract, including spaces and table).

Only one data table is permitted in the body of the abstract. Illustrations and/or figures are not allowed and will be deleted if submitted.

Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases. Commercial names may be included in the abstract text in parentheses with an ®, directly following the generic name at first use, i.e. "generic (Commercial ®)".

Abstracts cannot be revised once submitted.

The abstract must be submitted in English.

Physicians' Education Resource, LLC

Phone: 609-378-3701

Fax: 609-257-0705

Email: info@gotoper.com

Physicians' Education Resource, LLC

Phone: 609-378-3701

Fax: 609-257-0705

Email: info@gotoper.com